ColoVantage (methylated Septin 9 biomarker for colon cancer screening)

Home
Cancer Markers Blood Test
ColoVantage (methylated Septin 9 biomarker for colon cancer screening)

ColoVantage (methylated Septin 9 biomarker for colon cancer screening)

ColoVantage™ (methylated Septin 9)

NEW TEST. Option versus traditional fiber-optic colonocopy (CC). Used with FOBT (fecal occult blood test)

Detect circulating methylated DNA from the SEPT9 gene. Aid in the detection of colorectal cancer (CRC) in patients non-adherent to current testing modalities

Price:

$260.00

SKU:

m-Septin9 / 0016983

Product Description

ColoVantage™ (methylated Septin 9)

This test has a retail price of $355. EStatLabs is able to provide you this test for less. Our price is $260. That is a $95 savings on the typical cost of this new test. As this test becomes more popular the price will likely drop. A viable alternative for those who cannot afford a colonoscopy or who do not desire the more invasive colon cancer screening. Cost effective alternative as Colonoscopy can cost upwards of $1400 and come with complications not seen with blood tests.

For more information on ColoVantage please "search" this web site for an Article written by one of our Regional Medical Directors on the use of this test as a screening for colon cancer and as a cost savings alternative to standard fiberoptic colonoscopy.

Clinical Use

Detect circulating methylated DNA from the SEPT9 gene
Aid in the detection of colorectal cancer (CRC) in patients non-adherent to current testing modalities

Clinical Background

Colorectal cancer (CRC) is the fourth most common cancer in the United States; however, it is the second leading cause of cancer-related deaths. The high number of deaths is likely due to the following facts:

The 5-year survival rate dramatically drops from about 90% for patients diagnosed with early stage disease to 70% and 12% for those diagnosed with regional and distant stage disease, respectively.
Only about 40% of patients are diagnosed at an early stage.
Only about half of adults age 50 and over have been screened.

Current screening methods are either moderately invasive or require collection of a stool sample. Special patient preparation steps are often involved. These, among other things, may be barriers to screening.

ColoVantage represents an important medical advancement in that it is a plasma-based test that requires no patient preparation. It detects circulating methylated DNA from the SEPT9 gene, which is involved in cytokinesis and cell cycle control. A case-control study performed at Quest Diagnostics showed that the ColoVantage test is 70% sensitive for CRC detection at a specificity of 89%. ColoVantage has successfully detected cancer at all stages; however, the number of patients at each stage of cancer was too small to derive stage-specific sensitivity data. A similar test demonstrated a sensitivity of 67% and a specificity of 88% in a prospective study of almost 8000 people.

A physician may order the ColoVantage test for screen-eligible patients who have previously avoided established colorectal cancer screening methods such as colonoscopy, fecal occult blood tests, and fecal immunochemical tests (FITs). A patient whose ColoVantage test result is positive may be at increased risk for colorectal cancer and further evaluation should be considered. ColoVantage is not a replacement test for colonoscopy.

Read Article on ColoVantage and Colorectal Cancer Screening: http://www.estatlabs.com/news/6/Colon-Cancer-Screening-%252d-use-of-new-Biomarkers-%28ColoVantage%29.html

Interpretive Information

A patient whose ColoVantage test result is positive may be at increased risk for colorectal cancer and further evaluation should be considered.

Specimen Requirements: blood sample frozen serum sample

Source: Quest Diagnostics